Market Overview

Glaxo, Theravance Confirms FDA Panel Has Recommended Approval for UMEC/VI 62.5/25mcg Dose for COPD

Related GSK
Glaxo Looking into Misconduct Charges - Analyst Blog
Pharmaceutical Stocks For Income, Value And Growth Investors
Amgen, GSK End Marketing Pact for Osteoporosis Drug (Fox Business)
Related THRX
Theravance Announces Initiation of Phase 2b Study With TD-4208, an Investigational LAMA for the Treatment of COPD
Glaxo/Theravance Update on COPD Drugs - Analyst Blog

GlaxoSmithKline plc (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the Pulmonary-Allergy Drugs Advisory Committee (PADAC) to the US Food and Drug Administration (FDA) voted 11 yes to 2 no that the efficacy and safety data provide substantial evidence to support approval of umeclidinium/vilanterol (UMEC/VI, 62.5/25mcg dose) for the long-term, once-daily, maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

ANORO(TM) ELLIPTA(TM) is the proposed proprietary name for UMEC/VI, a combination of two investigational bronchodilator molecules -- GSK573719 or umeclidinium bromide (UMEC), a long-acting muscarinic antagonist (LAMA) and vilanterol (VI), a long-acting beta2 agonist (LABA), administered using the ELLIPTA(TM) inhaler.

The FDA Advisory Committee also voted that the safety of the investigational medicine has been adequately demonstrated at the 62.5/25mcg dose for the proposed indication (10 yes, 3 no), and the efficacy data provided substantial evidence of a clinically meaningful benefit for UMEC/VI 62.5/25mcg once daily for the long-term, maintenance treatment of airflow obstruction in COPD (13 yes, 0 no).

Posted-In: News FDA

 

Most Popular

Related Articles (THRX + GSK)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free